Zobrazeno 31 - 40
of 8 439
pro vyhledávání: '"35"'
Autor:
Anna-Lise Williamson, Hans-Ulrich Bernard, Itzel E. Calleja-Macias, Nubia Muñoz, Mina Kalantari, Luisa L. Villa, Magnus von Knebel-Doeberitz, Jose C. Prado, Heather A. Cubie, F. Xavier Bosch, Kate Cuschieri, R. J. Collins, Tang Yuan Chu, Cláudia R. F. Martins, Rosemary E. Zuna, Bruce Allan, S. Terence Dunn, Lap Ping Chung, Gloria I. Sanchez
Publikováno v:
Calleja-Macias, I E, Villa, L L, Prado, J C, Kalantari, M, Allan, B, Williamson, A-L, Chung, L-P, Collins, R J, Zuna, R E, Dunn, S T, Chu, T-Y, Cubie, H A, Cuschieri, K, von Knebel-Doeberitz, M, Martins, C R, Sanchez, G I, Bosch, F X, Munoz, N & Bernard, H-U 2005, ' Worldwide genomic diversity of the high-risk human papillomavirus types 31, 35, 52, and 58, four close relatives of human papillomavirus type 16 ', Journal of Virology, vol. 79, no. 21, pp. 13630-40 . https://doi.org/10.1128/JVI.79.21.13630-13640.2005
Among the more than one hundred formally described human papillomavirus (HPV) types, 18 are referred to as high-risk HPV types due to their association with anogenital cancer. Despite pathogenic similarities, these types form three remotely related t
Autor:
Gunilla B. Karlsson Hedestam, André Lieber, William C. Adams, Richard A. Koup, Ronald J. Berenson, Karin Loré
Publikováno v:
J Gen Virol
The complement-regulatory protein CD46 is the primary receptor for human adenovirus type 35 (HAdV-35) and can regulate human immune-cell activation. CD4 + T-cells are critical for initiating and maintaining adaptive immunity elicited by infection or
Association of Chlamydia pneumoniae Infection with HLA-B*35 in Patients with Coronary Artery Disease
Autor:
Ville Valtonen, Pekka Saikku, Mika Paldanius, Mikko Seppänen, Marja-Liisa Lokki, Anil Palikhe, Juha Sinisalo, Markku S. Nieminen, Maija Leinonen
Publikováno v:
Clinical and Vaccine Immunology. 15:55-59
The immune system may interplay between Chlamydia pneumoniae infection and coronary artery disease (CAD). Major histocompatibility complex genes regulate innate and adaptive immunity. Patients with CAD ( n = 100) and controls ( n = 74) were enrolled.
Autor:
Chris Duffy, Bin He, Edward Koo, Robert T. Bailer, Holly Trotter, Richard A. Koup, T. Manetz, Martha Nason, Rebecca L. Sheets, Judith Stein, Charla Andrews, Phillip Gomez
Publikováno v:
Journal of Immunotoxicology
The Vaccine Research Center has developed vaccine candidates for different diseases/infectious agents (including HIV-1, Ebola, and Marburg viruses) built on an adenovirus vector platform, based on adenovirus type 5 or 35. To support clinical developm
Publikováno v:
Journal of Virological Methods. 177:55-63
The use of adenovirus type 35 (Ad35) as a vector in vaccine and gene therapy studies is promising due to its broad cell tropism and low seroprevalence in humans. However, to date, a simple and effective system for producing recombinant Ad35 (rAd35) h
Autor:
Gilbert, Cornut, Simon, Gagnon, Catherine, Hankins, Deborah, Money, Karina, Pourreaux, Eduardo L, Franco, François, Coutlée, Julio, Montaner
Publikováno v:
Journal of Medical Virology. 82:1168-1178
The L1 gene encodes for the major capsid protein of human papillomaviruses (HPV). There is limited information on the polymorphism of L1 for types related to HPV-16. This report explores the polymorphism of L1 in phylogenetically related types 31, 33
Autor:
Fabienne DiGennaro, Karin Boucke, Nicole Liska, Silvio Hemmi, Urs F. Greber, Michele Gastaldelli, Menzo J. E. Havenga, Beat Amstutz, Nina Wolfrum, Stefan Kälin
Publikováno v:
Journal of virology
Journal of Virology, 10, 84, 5336-5350
Journal of Virology, 10, 84, 5336-5350
Human adenovirus serotype 35 (HAdV-35; here referred to as Ad35) causes kidney and urinary tract infections and infects respiratory organs of immunocompromised individuals. Unlike other adenoviruses, Ad35 has a low seroprevalence, which makes Ad35-ba
Autor:
Hiroaki Shibata, Takao Hayakawa, Shinichiro Nakamura, Keiji Terao, Akitomo K, Kenji Kawabata, Fuminori Sakurai, Hiroyuki Mizuguchi
Publikováno v:
Gene Therapy. 16:297-302
Adenovirus (Ad) serotype 35 (Ad35) vectors have attracted remarkable attention as alternatives to conventional Ad serotype 5 (Ad5) vectors. In a previous study, we showed that intravenously administered Ad35 vectors exhibited a safer profile than Ad5
Autor:
Shannon McGrath, Joe Cohen, Marie-Claude Dubois, Patrice M. Dubois, Jerome Custers, Maria Grazia Pau, V. Ann Stewart, Michelle Cobb, Jaap Goudsmit, Jack Komisar, Joseph P. Shott, Kent E. Kester, D. Gray Heppner, Olga J.A.E Ophorst, Marie-Ange Demoitié
Publikováno v:
Vaccine, 26(23), 2818-2823. Elsevier BV
Falciparum malaria vaccine candidates have been developed using recombinant, replication-deficient serotype 5 and 35 adenoviruses (Ad5, Ad35) encoding the Plasmodium falciparum circumsporozoite surface protein (CSP) (Ad5.CS, Ad35.CS) (Crucell Holland
Autor:
Catherine Hankins, Pierre Forest, Simon Gagnon, Cécile Tremblay, François Coutlée, Karina Pourreaux
Publikováno v:
The Journal of Infectious Diseases. 190:1575-1585
Background. Genetic polymorphism in human papillomavirus (HPV)-33 and -35 was investigated in 1055 sexually active women (732 human immunodeficiency virus [HIV] seropositive and 323 HIV seronegative).Methods. Consecutive genital specimens obtained at